The Sichuan company's 21 new products are eyeing the top five injections or the first reviews in the 10 billion market.

Before September 1st, Chengdu Bett Pharmaceuticals submitted a supplementary application for the consistent evaluation of cephalosporinehydrochloric acid, which was accepted by CDE contractor.
meters intranet data show that at present, Chengdu Bett (including subsidiaries) has submitted 24 generic drug consistency evaluation supplementary applications, 5 have been evaluated (2 for the first);
24 generics were reported in new categories, 3 were approved for production and evaluated (2 as the first); 7 of the 21 new varieties under review have not yet been approved for first imitation, and $1.5 billion has been exclusively reported by the company.
2 varieties were included in the third batch and successfully won the bid, are "barefoot varieties" (refers to the enterprise's market share in the varieties is low or 0).
19 consistent evaluation varieties are under review, the first of the five injection sprints on August 12, Chengdu Bett Pharmaceuticals submitted a supplementary application for injection cephalosporine hydrochloric acidconsistency evaluation was accepted by CDE contractor.
To date, 24 varieties of the company (including subsidiaries) have submitted applications for conformity evaluation supplements, 14 of which are systemic anti-infectants (12 are systemic anti-bacterial drugs);
meters of intranet data show that in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) chemical terminal systemic anti-infected drug market size of more than 200 billion yuan, an increase of 2.71% year-on-year, of which the whole-body anti-bacterial drug market size of more than 100 billion yuan.
table 1: Chengdu Beet in the review of the consistency evaluation of supplementary application varieties in the review of 19 varieties of consistent evaluation of supplementary applications in 11 public medical institutions in China in 2019 terminal sales of more than 1 billion yuan, injection cephalosporine, hydrochloric acid right metomycin injection, injection of cephalosporine sodium, hydrochloride bromoso injection, injection of omeprazole 5 varieties sold more than 3 billion yuan per year.
17 of the 19 varieties were injections, compared with 2018, 9 injections in China's public medical institutions in 2019 end-sales growth, hydrochloric acid right metomycin injection, injection of cephalosporin sodium, injection of cephalosporine sodium, thiopental injection 4 varieties increased by more than 10%.
In addition to the hydrochloric acid right metomedin injection, hydrochloride bromoso injection, cephalosporineparticles, injection of azithromycin, thioic acid injection 5 varieties, the remaining 14 varieties under review have not yet been evaluated by enterprises; Injection, injection of sodium cephalosporine, injection of sodium cephalosporine, injection of sodium cephalosporine, injection of ozagrain sodium 5 varieties by Chengdu Pt first declared consistency evaluation, of which the sodium phosphate injection, injection of sodium ampicillin for exclusive declaration.
The first evaluation rate of 50%, 2 large "light feet" varieties to be put on the scale 2: Chengdu Beit has been evaluated varieties of mi-net consistency evaluation database shows that the current Chengdu Bett Pharmaceuticals through or as if through consistency evaluation of the varieties have 8, of which 4 are the first over-evaluation, ketoagine triamcinol injection, fluorconazole capsules for exclusive evaluation;
currently carried out in the national collection, Chengdu beet the "barefoot enterprises" called (refers to the collection of related varieties of the market blank or accounted for a small proportion of enterprises).
In the 4 plus 7 episodes, Chengdu Bett's cephalosporine tablets, fumarate nofove diamide tablets won the bid, the company in these two varieties have a market share of about 5%; In the harvest, Chengdu Beit's fluoroconazole capsule winning bid, the company's market share in this variety is basically 0;
Table 3: Chengdu Bett's third batch of collected varieties competition pattern Chengdu Beit's non-nahetamine tablets listed for many years, but in China's public medical institutions terminal sales have not been improved;
Chengdu Bett these two "barefoot varieties" successfully winning the bid, will become a great opportunity to open up the market.
keep a close eye on the 10 billion market, 21 new products on the road on August 12, Hainan Beit (Chengdu Beit subsidiary) to copy 4 categories of submitted applications for the listing of injection volifiazole to obtain CDE contractor acceptance, currently Chengdu Bett has 24 generic drugs to the new classification of production.
From the treatment category, the whole body anti-infector drugs are still the main area of Chengdu Pepper, followed by neurological drugs, respectively, 7, 5 varieties reported production;
Table 4: Chengdu Bett reports on the review of generic drugs with a new classification 21 generic drugs in 2019 China's public medical institutions terminal total sales of more than 10 billion yuan, injection of voliconazole, non-busta tablets, phosphorus Osetawe acid capsules, metformin hydrochloric acid slow release tablets, pyrithione chloride tablets (I.), inhalation with Budinide mixed suspension, injection with esomerazole sodium 7 varieties sold more than 1 billion per year.
7 varieties have not yet been approved for the market, including hydrobrominate vulcanization tablets, phosphate estamircan suspension agent, methionate lunvatini capsules, entourtabin propofol nofoweis tablets, hydrochloric acid right metominated sodium chloride injections, head spores, fumatinol novowe tablets.
of which Entourtabin propofol is produced exclusively by Chengdu Vet in a new category, developed by Gilead and with global sales of $1.5 billion in 2019.
sources: MED2.0 China Drug Review Database, China's public medical institutions terminal competition pattern Note: data statistics as of August 28, if there are omissions, welcome to point out!